Attached files
file | filename |
---|---|
EX-99.1 - INVESTOR PRESENTATION - Medite Cancer Diagnostics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported):
|
December 14, 2016
|
MEDITE CANCER DIAGNOSTICS,
INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
333-143570
|
36-4296006
|
(Commission File
Number)
|
(IRS
Employer Identification No.)
|
4203 SW 34th St.
|
|
Orlando,
FL
|
32811
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
On
December 14, 2016, MEDITE Cancer Diagnostics, Inc. (the
“Company”) filed a Current Report on Form 8K which
included as Exhibit 99.1 to the Current Report an investor
presentation which may be presented at meetings with investors,
analysts, and others, in whole or in part and possibly with
modifications, during the fiscal year ending December 31, 2016 and
December 31, 2017. The Exhibit 99.1 filed in the previous Current
Report contained an error citing an offering which had previously
been closed by the Company. The Company therefore amends the
Current Report to provide the corrected Exhibit 99.1.
By
filing this amendment to the Current Report on Form 8-K and
furnishing the information contained herein, the Company makes no
admission as to the materiality of any information in this amended
Current Report that is required to be disclosed solely by reason of
Regulation FD. The information contained in the investor
presentation is summary information that is intended to be
considered in the context of the Company's Securities and Exchange
Commission (“SEC”) filings and other public
announcements that the Company may make, by press release or
otherwise, from time to time. The Company undertakes no duty or
obligation to publicly update or revise the information contained
in this amendment to the Current Report, although it may do so from
time to time as its management believes is warranted. Any such
updating may be made through the filing of other reports or
documents with the SEC, through press releases or through other
public disclosure.
The
information presented in Item 7.01 of this amended Current Report
on Form 8-K and Exhibit 99.1 shall not be deemed to be
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, unless the
Company specifically states that the information is to be
considered “filed” under the Exchange Act or
specifically incorporates it by reference into a filing under the
Securities Act of 1933, as amended, or the Exchange
Act.
Item 9.01 Financial
Statements and Exhibits.
Exhibit Description
99.1
Investor Presentation
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
Date:
December 22, 2016
|
By:
|
/s/ David Patterson
|
|
|
David
Patterson
|
|
|
Chief
Executive Officer
|